Haemonetics Corp
corporate_fare Company Profile
Haemonetics Corp (NYSE:HAE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for HAE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for HAE spans 8-K, DEF 14A, 10-K, 10-Q.
Recent high-impact activity:
- Haemonetics Posts $358M in Q2 Revenue
- Haemonetics Lifts FY27 Revenue Guidance to 8-11% on 10% Organic Q2 Growth
- FDA Approves PerQseal Elite, Opening U.S. Large-Bore Closure Market
- CSL to Complete Haemonetics Platform Rollout in US Plasma Centers by End 2027
- Haemonetics Signs Non-Exclusive Supply Agreement with CSL Plasma for NexSys PCS Devices
Financial Snapshot
Short Interest & Short Volume
6.27 days to coverFINRA reported short interest of 3,599,250 shares in HAE as of the October 30, 2026 settlement, a 5.0% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 79.7% of HAE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.